T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLB Ltd
SLB
|
+$2.48B |
| 2 |
Kenvue
KVUE
|
+$1.5B |
| 3 |
Halliburton
HAL
|
+$1.12B |
| 4 |
Boeing
BA
|
+$950M |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$920M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.64B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Advanced Micro Devices
AMD
|
+$1.66B |
| 4 |
Johnson & Johnson
JNJ
|
+$1.56B |
| 5 |
Amazon
AMZN
|
+$1.17B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.76% |
| 2 | Healthcare | 16.83% |
| 3 | Financials | 10.91% |
| 4 | Consumer Discretionary | 10.77% |
| 5 | Communication Services | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2776
Rayonier Advanced Materials
RYAM
$573M
| $49K | ﹤0.01% |
13,820
+1,897
| +16% | +$7.12K |
|
2777
Barnwell Industries
BRN
$13.9M
| $48K | ﹤0.01% |
18,200
| – | – |
|
|
NGM
2778
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $48K | ﹤0.01% |
44,286
-2,677
| -6% | -$5.54K |
|
2779
Sutro Biopharma
STRO
$356M
| $46K | ﹤0.01% |
1,311
+156
| +14% | +$6.8K |
|
2780
CorMedix
CRMD
$648M
| $45K | ﹤0.01% |
+12,073
| New | +$48K |
|
2781
Intellicheck
IDN
$74.1M
| $44K | ﹤0.01% |
19,500
| – | – |
|
2782
MediciNova
MNOV
$64.5M
| $44K | ﹤0.01% |
20,700
| – | – |
|
|
CANO
2783
DELISTED
Cano Health, Inc.
CANO
| $43K | ﹤0.01% |
1,693
+24
| +1% | +$1.97K |
|
2784
Aemetis
AMTX
$124M
| $42K | ﹤0.01% |
10,100
| – | – |
|
|
OLPX
2785
DELISTED
Olaplex Holdings
OLPX
| $42K | ﹤0.01% |
21,442
+1,537
| +8% | +$4.63K |
|
|
VINC
2786
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $42K | ﹤0.01% |
+2,000
| New | +$38.8K |
|
|
SRT
2787
DELISTED
Startek Inc.
SRT
| $42K | ﹤0.01% |
12,800
| – | – |
|
2788
Compass Therapeutics
CMPX
$412M
| $41K | ﹤0.01% |
20,463
+1,942
| +10% | +$4.8K |
|
2789
Humacyte
HUMA
$167M
| $41K | ﹤0.01% |
13,936
+1,932
| +16% | +$6.39K |
|
2790
Expensify
EXFY
$198M
| $40K | ﹤0.01% |
12,212
+1,011
| +9% | +$5.46K |
|
|
BMTX
2791
DELISTED
BM Technologies, Inc.
BMTX
| $40K | ﹤0.01% |
19,800
| – | – |
|
2792
Cue Biopharma
CUE
$122M
| $39K | ﹤0.01% |
555
| – | – |
|
2793
Outdoor Holding Co
POWW
$261M
| $39K | ﹤0.01% |
18,996
| – | – |
|
|
SUNW
2794
DELISTED
Sunworks, Inc.
SUNW
| $39K | ﹤0.01% |
73,400
| – | – |
|
2795
ESS Tech
GWH
$19.5M
| $38K | ﹤0.01% |
1,343
+353
| +36% | +$8.59K |
|
2796
Ocugen
OCGN
$465M
| $38K | ﹤0.01% |
94,100
+62,800
| +201% | +$31K |
|
2797
Workhorse Group
WKHS
$34M
| $38K | ﹤0.01% |
30
+2
| +7% | +$5.14K |
|
2798
TeraWulf
WULF
$8.28B
| $38K | ﹤0.01% |
29,542
+15,435
| +109% | +$36.6K |
|
|
DNMR
2799
DELISTED
Danimer Scientific, Inc.
DNMR
| $38K | ﹤0.01% |
456
| – | – |
|
2800
BARK
BARK
$95.4M
| $37K | ﹤0.01% |
1,539
+462
| +43% | +$12.8K |
|
Similar funds
T. Rowe Price Associates's Q3 2023 Portfolio in Review
As of Q3 2023, T. Rowe Price Associates held 2,959 positions worth $682B, down 4.9% from $718B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Trading was light in Q3 2023: portfolio turnover was 4.7%. T. Rowe Price Associates opened 69 new positions and exited 71, leaving the 2,959-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 32% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q3 2023 buy was Maplebear: 6,435,942 shares worth $191M.
- T. Rowe Price Associates added most to SLB Ltd in Q3 2023, an estimated $2.48B increase.
- T. Rowe Price Associates's biggest Q3 2023 reduction was Microsoft, cutting an estimated $2.64B.
- T. Rowe Price Associates fully exited Life Storage, Inc. in Q3 2023, selling an estimated $285M.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $682B portfolio in Q3 2023.
- T. Rowe Price Associates opened 69 new positions and closed 71 in Q3 2023.
- T. Rowe Price Associates's portfolio value fell 4.9% quarter-over-quarter to $682B.
Based on T. Rowe Price Associates's 13F filing for Q3 2023, filed 14 Nov 2023.